To hear about similar clinical trials, please enter your email below
Trial Title:
Ate-Bev Early Response Prediction Model in Advanced HCC
NCT ID:
NCT05763277
Condition:
Hepatocellular Carcinoma
Atezolizumab-bevacizumab
Response Evaluation
Conditions: Official terms:
Carcinoma
Carcinoma, Hepatocellular
Study type:
Observational [Patient Registry]
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
Early response evaluation
Description:
Atezolizumab and bevacizumab are administered every three weeks, and before to the second
treatment cycle, blood tests and imaging tests are conducted (week 5). This precedes the
standard response evaluation (week 9-12).
Arm group label:
Ate-Bev
Summary:
The prognosis of hepatocellular carcinoma is poor compared to other carcinomas. Many
drugs have recently been developed, and recently, atezolizumab-bevacizumab treatment was
superior to sorafenib, the conventional treatment for advanced hepatocellular carcinoma.
However, there is no information on the evaluation on the evaluation of treatment
response for atezolizumab-bevacizumab combination therapy compared to atezolizumab alone
or bevacizumab alone. Therefore, this study aimed to create a predictive model that can
detect treatment response at an early stage.
Criteria for eligibility:
Study pop:
Patients who were diagnosed with advanced hepatocellular carcinoma and who were scheduled
to receive atezolizumab-bevacizumab as the first-line therapy in a single tertiary
hospital are included.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Patients who were diagnosed with advanced hepatocellular carcinoma and who were
scheduled to receive atezolizumab-bevacizumab as the first-line therapy
- Patients willing to participate in this study
Exclusion Criteria:
- Individuals with a history of severe contrast allergy
- Individuals with severe comorbidities (according to the American Society of Clinical
Oncology-Friends of Cancer Research Organ Dysfunction.)
Gender:
All
Minimum age:
18 Years
Maximum age:
80 Years
Healthy volunteers:
Accepts Healthy Volunteers
Locations:
Facility:
Name:
Seoul National University Hospital
Address:
City:
Seoul
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
Jeong-Hoon Lee, M.D., Ph.D.
Email:
pindra@empal.com
Start date:
July 22, 2022
Completion date:
May 22, 2025
Lead sponsor:
Agency:
Seoul National University Hospital
Agency class:
Other
Source:
Seoul National University Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05763277
